The Legal Landscape of Performance-Enhancing Substances

Why the legal category matters

US law has no single rule for "performance-enhancing substances." It sorts them into categories, and the category decides who is breaking the law. Anabolic steroids are controlled substances, so holding them without a prescription is a crime in itself. Most peptides sold online are unapproved drugs instead, and the legal risk falls mainly on whoever sells them.

This page shows where peptides fit next to steroids and SARMs, and what changed in 2026. Our detailed US peptide regulations page has the full federal rulebook, and the legal status hub maps the rest of the category.

How the categories compare

The table summarizes the main federal categories as of October 2026. It isn't legal advice. State law can add its own restrictions.

Steroids and SARMs took different paths

Anabolic steroids are listed in Schedule III of the Controlled Substances Act. Under 21 U.S.C. 844, a first offense of simple possession without a valid prescription carries up to a year in prison and a minimum $1,000 fine. Selling them is punished more heavily.

The prohormone era shows how scheduling closes a gap. Supplement makers once sold steroid precursors that weren't on the list. The Anabolic Steroid Control Act of 2004 rewrote the definition of "anabolic steroid" to name precursors such as androstenedione and THG.

SARMs never got that treatment. As of October 2026, they aren't federally scheduled. The SARMs Control Act, introduced in the Senate in 2019, died without a vote, and we found no bill moving now. FDA says SARMs "cannot be legally marketed in the U.S. as a dietary supplement or drug," even when sold for research use only. That leaves them in the same legal spot as most research peptides: unapproved drugs, with enforcement aimed at sellers.

Growth hormone is its own case. Under 21 U.S.C. 333(e), knowingly distributing HGH for any use other than an FDA-authorized treatment ordered by a physician carries up to five years in prison. Peptides that prompt the body to release its own growth hormone are different molecules. Ipamorelin is one example, and it falls under the general drug rules.

Peptides are judged by intended use

US law has no separate category for peptides. A peptide meant for use in people is a drug, and selling a new drug across state lines without FDA approval violates sections 301(d) and 505(a) of the FD&C Act.

FDA's regulation on intended use (21 CFR 201.128) says intent is judged objectively. Labeling claims and advertising can show it. So can the circumstances in which a product is sold. A "research use only" line is one statement on the label, and FDA reads it against everything else the seller does.

Research-use-only enforcement in 2026

FDA's 2026 warning letters show how that works. On March 31, 2026, it told Gram Peptides that its retatrutide and tirzepatide were unapproved new drugs, as was the bacteriostatic water it sold. The labels said "Research Use Only," but the website's claims about appetite and glucose control showed the products were meant for people.

FDA's August 24, 2026 letter to Peak Performance Peptides named five peptides. Semaglutide and tesamorelin were among them. FDA treated the seller's bacteriostatic water as a drug too, because selling it alongside the peptides provided "the means to prepare an injectable drug for human administration."

Criminal cases are rarer. On July 30, 2026, a federal judge in Indiana sentenced Paradigm Peptides owner Matthew Kawa to 70 months in prison, according to CBS News. He had pleaded guilty to selling unapproved drugs and importing them illegally. He admitted knowing the company's research-labeled products were sold for human consumption. He also admitted it forged lab certificates. Our page on peptide legal cases covers this prosecution and others.

Every action above targeted a seller. None of the 2026 federal actions we reviewed charged someone only for buying peptides for personal use. That's an observation about enforcement so far, not a legal protection.

Compounding: what changed in 2026

For peptides with no approved version, a compounding pharmacy is the main lawful route, and it still requires a prescription.

503A pharmacies

A 503A pharmacy compounds for individual patients. It can use a bulk ingredient with a USP or NF monograph, or one that's part of an approved drug. Anything else has to be on FDA's 503A bulks list, and most peptides aren't. While nominations are under review, FDA uses interim categories. It doesn't plan to act against compounding with Category 1 substances. Category 2 means FDA has found significant safety concerns.

In 2023, FDA put many popular peptides into Category 2, BPC-157 among them. In 2026, that changed in stages:

• April: On April 15, FDA announced it would remove 12 peptides from Category 2 because their nominators had withdrawn the nominations. BPC-157 and TB-500 were on the list. Removal isn't permission to compound. According to the law firm Frier Levitt, these peptides now sit outside the interim policy, which protects only Category 1.
• July 23-24: FDA's Pharmacy Compounding Advisory Committee (PCAC) recommended six of seven reviewed peptides for the bulks list, BPC-157 and TB-500 among them, although FDA staff said none was well characterized. The committee voted against DSIP.
• Since then: A committee vote is advice. Adding a substance to the list takes notice-and-comment rulemaking, and as of October 2026 we found no proposed rule. A second PCAC meeting on five more peptides is planned before the end of February 2027.

503B outsourcing facilities and GLP-1s

503B outsourcing facilities compound in larger batches from a separate bulks list. On April 30, 2026, FDA proposed keeping semaglutide off it, with the same proposal for tirzepatide and liraglutide. It found no clinical need to compound them from bulk powder while approved versions are available. As of October 2026, we found no final decision.

Imports and customs

The border is a second pressure point. Customs and Border Protection (CBP) officers in Cincinnati seized about 5,000 mis-manifested peptide shipments from a shipper in China between December 2025 and late March 2026. CBP said they included GLP-1 drugs such as retatrutide, along with peptides like MOTS-c.

For GLP-1 ingredients, FDA's Import Alert 66-80 lets border staff detain foreign shipments without examination unless the maker is on FDA's "Green List." FDA last revised it in October 2026.

Individuals face limits too. FDA's personal importation page says importing drugs for personal use is illegal "in most circumstances." Staff have some discretion, mainly for serious conditions with no effective US treatment and generally up to a three-month supply. Peptides bought for performance goals rarely fit that description.

Prescription peptides

A few peptides that lifters discuss are approved drugs. Approval covers a specific product and use, not every vial of the same compound.

• Tesamorelin (Egrifta WR) is approved to reduce excess abdominal fat in HIV-infected adults with lipodystrophy. Its label says it is "not indicated for weight loss management." Forum users commonly discuss it for fat loss, which is outside the label.
• Semaglutide is approved as Wegovy for weight management in adults with obesity, or with overweight plus a weight-related condition. It comes as a weekly injection and, since December 2025, a daily tablet.

Both are prescription medicines. The August 2026 warning letter shows where the line falls: FDA treated research-labeled semaglutide and tesamorelin as unapproved new drugs, even though approved versions exist. FDA has reviewed the approved products for identity and sterility. Nobody has done that for a research vial, and in the Paradigm case even the lab certificates were forged. Our guide to peptide sourcing and quality control explains what a certificate of analysis can tell you.

Sport has its own rulebook

Tested athletes answer to anti-doping rules on top of drug law. WADA's Prohibited List applies whatever a peptide's FDA status. Our page on competitive sports rules covers where each peptide sits.

What to watch next

• FDA's next step on the six peptides the PCAC backed: a proposed rule, or a faster interim Category 1 placement.
• The second advisory committee meeting, due by the end of February 2027.
• A final 503B decision on the three GLP-1 drugs.
• Whether the 2026 warning letters lead to more prosecutions like the Paradigm case.